Vericel expects full-year 2019 total revenue in the range of $116 to $118 million
The company believes the target addressable market for MACI is still underpenetrated and expects to maintain double-digit growth in the years ahead
Vericel plans to expand their MACI sales force to 76 territories (49 currently) in six to nine regions by 2Q20
Leadership believes that the number of biopsies received is the best indicator of future sales performance; the company received biopsies from 1,300 surgeons in the last four quarters, up 26% from the four quarters ending 3Q18
ORTHOWORLD projects Vericel full year 2019 MACI revenue of $88 million, +30% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Orthobiologics
$20.6
$16.4
$4.2
25.3%
9Mo 19
9Mo 18
$ Chg
% Chg
Orthobiologics
$58.0
$42.6
$15.4
36.1%
Earnings
Amt
% of Sales
Sales
$30.4
Cost of Sales
($9.3)
30.6%
Selling and Admin
($15.0)
49.2%
R & D
($3.1)
10.2%
Other
$0.4
1.4%
Net Earnings
$3.5
11.4%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Vericel expects full-year 2019 total revenue in the range of $116 to $118 million The company believes the target addressable market for MACI is still underpenetrated and expects to maintain double-digit growth in the years ahead Vericel plans to expand...
Vericel expects full-year 2019 total revenue in the range of $116 to $118 million
The company believes the target addressable market for MACI is still underpenetrated and expects to maintain double-digit growth in the years ahead
Vericel plans to expand their MACI sales force to 76 territories (49 currently) in six to nine regions by 2Q20
Leadership believes that the number of biopsies received is the best indicator of future sales performance; the company received biopsies from 1,300 surgeons in the last four quarters, up 26% from the four quarters ending 3Q18
ORTHOWORLD projects Vericel full year 2019 MACI revenue of $88 million, +30% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
3Q19
3Q18
$ Chg
% Chg
Orthobiologics
$20.6
$16.4
$4.2
25.3%
9Mo 19
9Mo 18
$ Chg
% Chg
Orthobiologics
$58.0
$42.6
$15.4
36.1%
Earnings
Amt
% of Sales
Sales
$30.4
Cost of Sales
($9.3)
30.6%
Selling and Admin
($15.0)
49.2%
R & D
($3.1)
10.2%
Other
$0.4
1.4%
Net Earnings
$3.5
11.4%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
